Researchers studied a drug called damoctocog alfa pegol in children with severe haemophilia A. The study included 35 children, aged 7 to under 12, who had been treated for haemophilia before. The main goal was to check the drug's safety over the first few doses and its ability to prevent bleeds over six months.
No child had to stop the drug because of a bad reaction. About 60% of children had at least one mild or moderate side effect, but none were severe. The drug continued to protect children from bleeds. One child had a temporary break in treatment because the drug seemed to stop working as well for a time.
It is important to be careful with these results. This was an 'open-label' study, meaning everyone knew which drug was being given, and there was no comparison group getting a different treatment. This makes it harder to be certain about the drug's effects. The study was also relatively small and only lasted six months.
For now, this study suggests the drug may be a safe option for children in this age group, but longer and more controlled studies are needed to confirm these early findings.